-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNTY-101 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNTY-101 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CNTY-101 in Primary Mediastinal B-Cell Lymphoma Drug Details: CNTY-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNTY-101 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNTY-101 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CNTY-101 in Follicular Lymphoma Drug Details: CNTY-101 (CAR-iNK cell therapy) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNTY-101 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNTY-101 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CNTY-101 in Marginal Zone B-cell Lymphoma Drug Details: CNTY-101...
-
Sector Analysis
COVID-19 Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
COVID-19 tests Market Report Overview The COVID-19 tests market size was valued at $23.97 billion in 2023. The market will decline at a CAGR of more than 22%. COVID-19 tests are used to screen for and identify infections caused by the SARS-CoV-2- coronavirus, an emerging pathogen that was first discovered in China in the early 21st century. The COVID-19 test can be performed using point-of-care rapid testing, laboratory-based ELISA testing, or PCR. COVID-19 Tests Market Outlook 2023-2033 ($ Billion) Buy...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Marginal Zone B-cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Marginal Zone B-cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Analyst Opinions
Oil and Gas Sector Strategies in Carbon Capture Utilization and Storage
Oil and Gas Sector Strategies in Carbon Capture Utilization and Storage Report Overview The total number of carbon capture utilization and storage (CCUS) projects was 66 in 2023. From 2023 to 2030, active CCUS capacity will increase at a CAGR of more than 37%. A strong increase in the number and maximum capacity of CCUS projects is expected as more commercial-scale projects become active in the coming years. CCUS will become an increasingly prominent emission reduction technology as the scale...
-
Product Insights
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Taka Kyocera Solar PV Park
Taka Kyocera Solar PV Park is a solar PV project located in Hyogo, Japan. The project is owned by Kyocera Corp; Mitsubishi Research Institute Inc; Tokyo Century Corp; Yonden Engineering Corporation and was developed by Kyocera Corp; Tokyo Century Corp; Yonden Engineering Corporation. The project came online in 2016. Empower your strategies with our Taka Kyocera Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report...